Compare QNCX & PRSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | QNCX | PRSO |
|---|---|---|
| Founded | 2012 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Semiconductors |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.9M | 7.8M |
| IPO Year | 2019 | 2000 |
| Metric | QNCX | PRSO |
|---|---|---|
| Price | $1.33 | $1.00 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | ★ 63.5M | 514.4K |
| Earning Date | 04-10-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 81.23 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $14,573,000.00 |
| Revenue This Year | N/A | $18.48 |
| Revenue Next Year | N/A | $53.57 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 5.99 |
| 52 Week Low | $0.08 | $0.75 |
| 52 Week High | $4.55 | $2.37 |
| Indicator | QNCX | PRSO |
|---|---|---|
| Relative Strength Index (RSI) | 73.92 | 47.27 |
| Support Level | $0.10 | $0.81 |
| Resistance Level | $1.47 | $1.05 |
| Average True Range (ATR) | 0.15 | 0.05 |
| MACD | 0.08 | 0.01 |
| Stochastic Oscillator | 86.11 | 58.22 |
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.
Peraso Inc is a fabless semiconductor company focused on the development and sale of: i) millimeter wavelength wireless technology, or mmWave, semiconductor devices and antenna modules based on its proprietary semiconductor devices and ii) performance of non-recurring engineering, or NRE, services and licensing of intellectual property, or IP. The company's primary focus is the development of mmWave, which is generally described as the frequency band from 24 Gigahertz, or GHz, to 300 GHz. Geographically the company generates revenue from the United States, Hong Kong, Taiwan, and the Rest of the World.